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Abstract
Introduction The global burden of type 2 diabetes
(T2DM) is steadily increasing. Experimental studies
have demonstrated that a novel hormone secreted by
bone cells, osteocalcin (OC), can stimulate beta-cell
proliferation and improve insulin sensitivity in mice.
Observational studies in humans have investigated the
relationship between OC and metabolic parameters, and
T2DM. Importantly, few studies have reported on the
undercarboxylated form of OC (ucOC), which is the putative
active form of OC suggested to affect glucose metabolism.
Objectives We will conduct a systematic review and
meta-analysis to: (1) compare the levels of serum OC and
ucOC between T2DM and normal glucose-tolerant controls
(NGC); (2) investigate the risk ratios between serum
OC and ucOC, and T2DM; (3) determine the correlation
coefficient between OC and ucOC and fasting insulin
levels, homeostatic model assessment-insulin resistance,
haemoglobin A1c and fasting glucose levels and (4)
explore potential sources of between-study heterogeneity.
The secondary objective is to compare the serum OC and
ucOC between pre-diabetes (PD) and NGC and between
T2DM and PD.
hods and analysis This study will report items in
line with the guidelines outlined in preferred reporting
items for systematic reviews and meta-analysis of
observational studies in epidemiology. We will include
observational studies (cohort, case-control and crosssectional studies) and intervention studies with baseline
data. Three databases (MEDLINE, EMBASE and SCOPUS)
will be searched from inception until July 2018 without
language restrictions. Two reviewers will independently
screen the titles and abstracts and conduct a full-text
assessment to identify eligible studies. Discrepancies will
be resolved by consensus with a third reviewer. The risk
of bias assessment will be conducted by two reviewers
independently based on the Newcastle-Ottawa Scale.
Potential sources of between-study heterogeneity will be
tested using meta-regression/subgroup analyses. Contourenhanced funnel plots and Egger’s test will be used to
identify potential publication bias.
Ethics and dissemination Formal ethical approval is
not required. We will disseminate the results to a peerreviewed publication and conference presentation.
PROSPERO registration number CRD42017073127.

Strengths and limitations of this study
►► This review will propose a sensitive search strategy

to include more eligible observational studies (cohort, case-control and cross-sectional studies) than
previous meta-analyses.
►► The review will assess and synthesise data on both
forms of osteocalcin (OC; total OC and undercarboxylated OC [ucOC]), potentially being more relevant to
the endocrine function in humans.
►► The design of the review considers the early to late
stages of diabetes, which will indicate whether the
relationship between OC and impaired glucose metabolism is altered during progressively poorer glucose control.
►► Sources of heterogeneity will be explored using meta-regression/subgroup analyses.
►► The main limitation of the current study is only including observational studies (cohort, case-control
and cross-sectional studies).

Introduction
The disease burden attributed to diabetes is
high. Currently, around 425 million people
have diabetes, with 90% of these having
type 2 diabetes (T2DM).1 It is estimated
that by 2045, this figure will have increased
to 629 million people.1 Patients with T2DM
present increased levels of glucose than
people with normal glycaemic metabolism.
Also, those patients have increased risks of
other complications, such as heart attacks,
strokes, diabetic retinopathy and renal
disease.2
Correspondingly, several organs become
the targets to treat, prevent or predict
diabetes, such as pancreatic beta cells, muscle,
liver, adipose tissue, kidney, the gastrointestinal tract or the brain.3 Interestingly, a recent
study has identified a new potential tissue
to treat diabetes: the skeleton and bone.
Increasing numbers of osteokines secreted by
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a need for up-to-date systematic review/meta-analysis. In
2017, Takashi et al showed that ucOC could predict insulin
secretion in patients with T2DM.22 They conducted the
study in 41 Japanese patients with T2DM with a mean
age of about 59 years22 The result showed a correlation
between ucOC and homeostatic model assessment of
beta-cell function (r=0.36, P=0.011).22 In a cross-sectional
study of 69 volunteers, OC was found to be suppressed
with insulin resistance, regardless of obesity or fat mass
at significantly lower levels shown in controls compared
with T2DM or insulin resistant obesity.23 However, only
a few interventional studies/clinical trials were found
in our scope search in MEDLINE (online appendix 1).
Only three clinical studies were conducted after 2015 and
might be eligible for inclusion in the present review.24–26
Ghiraldini et al designed a clinical trial in 32 T2DM
patients and 19 patients without diabetes. Baseline data
indicated that OC levels were higher in systematically
healthy patients than those with better-controlled T2DM
while poorly controlled T2DM patients had the highest
OC levels.26
Some observational studies have reported decreased
OC concentrations in pre-diabetics (PD) compared
with normal glucose tolerance controls, while Aoki
et al indicated an increase in OC concentration during
the early stage of diabetes.27–29 Therefore, conducting
meta-analyses comparing the OC levels between PD
and normal glucose controls and comparing OC levels
between T2DM and PD may contribute to the investigation between OC and glucose homeostasis in patients
with diabetes.
Another unsolved issue in the previously published
meta-analyses is the high between-study heterogeneity.
Previous reviews explored different sources of heterogeneity with modest success.19 20 Starup-Linde et al
conducted subgroup analysis according to sex, age and
menopausal status in women.30 Liu C et al attempted to
explain the heterogeneity by sex and OC assay methods.20
Kunutsor et al conducted subgroup analyses according
to study design and degree of confounders of risk estimates.19 Hygum et al performed a meta-regression analysis to investigate the extent to which heterogeneity was
explained by haemoglobin A1c (HbA1c) levels.21
Therefore, the present systematic review/meta-analysis will use a more comprehensive search strategy to
identify more prospective studies, thereby increasing
the statistical power. Second, we will search for studies
reporting the association between ucOC and glucose
metabolism. Third, we will identify studies comparing
the OC concentrations between PD and normal glucose
controls, and between T2DM and PD. Lastly, by systematically exploring potential sources of heterogeneity we may
explain previous conflicting findings.
Objectives
The present systematic review and meta-analysis aims to:
(1) compare the levels of serum OC and ucOC between
Liu Y, et al. BMJ Open 2019;9:e023918. doi:10.1136/bmjopen-2018-023918
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skeleton and bone exhibit regulatory function in glucose
metabolism.3
Osteocalcin (OC) is an osteoblast-secreted protein that
plays a role in the communication between the skeleton
and glucose homeostasis. There are two forms of OC:
undercarboxylated osteocalcin (ucOC) and carboxylated
osteocalcin (cOC).4 cOC contributes to the extracellular
bone matrix, while ucOC is likely the active form of OC in
the circulation.5 Both cOC and ucOC are present in the
circulation, and their combined amount is referred to as
total osteocalcin (TOC).5 TOC is considered a marker of
bone turnover.6
A potential endocrine function of OC was first suggested
in 2007. Lee et al and Ferron et al reported OC-mediated
glucose homeostasis via stimulating beta-cell proliferation and adiponectin secretion in mice.7 8 The endocrine
actions of OC involve increasing insulin synthesis and
secretion by beta-cells and improved insulin sensitivity
by promoting adiponectin secretion in adipocytes.7 8 The
high-fat diet experimental study revealed that bone could
become insulin resistant by inhibiting the activation of
OC.9 However, reported associations between OC and
T2DM in humans have yielded conflicting results.10–13
Lerchbaum et al reported that high OC level was associated with reduced risk of developing T2DM in a population-based study (OR, 0.57; 95% CI: 0.46 to 0.70).14 In
a cross-sectional study of patients with poorly controlled
T2DM, Achemlal et al reported that serum levels of OC were
significantly lower in T2DM compared with age-matched
controls,15 while Bao et al observed that increased serum
levels of OC were associated with improved glucose
control.16 Yeap et al found that both TOC and ucOC were
associated with reduced risk of diabetes in a cohort of
community-dwelling elderly men (OR, 0.60; 95% CI: 0.50
to 0.72 for TOC, and OR, 0.55; 95% CI: 0.47 to 0.64 for
ucOC).17 In contrast, a case-control study conducted by
Zwakenberg et al with 1635 participants indicated a lack
of association between TOC/ucOC and the risk of T2DM
(OR, 0.97; 95% CI: 0.69 to 1.36 for TOC, and OR, 0.88;
95% CI: 0.61 to 1.27 for ucOC).18
Two previously published systematic reviews/meta-analyses reported decreased serum levels of TOC in people
with T2DM compared with controls in 2015. However,
these reviews only found a small number of published
studies and did not investigate ucOC.19–21 The mean
differences in T2DM compared with normal glucose
tolerance controls from the three reviews showed similar
results (−3.31 ng/mL (−4.04, –2.57) from Kunutsor et al;
−2.87 ng/mL (−3.76,–1.98) from Liu C et al and −2.51 ng/
mL (−3.01,–2.01) from Hygum et al).19–21 Both of the
reviews by Kunutsor et al and Liu C et al only found a
small number (n=4) of cohort studies.19 20 In addition,
studies reporting the associations between ucOC and
glucose homeostasis in T2DM have not been adequately
meta-analysed.20
An increasing number of epidemiological studies have
been continuously published in the recent 3 years following
two systematic reviews/meta-analyses in 2015, signalling
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The process of the proposed protocol.

T2DM and normal glucose-tolerant controls (NGC); (2)
investigate the risk ratios between serum OC and ucOC,
and T2DM; (3) determine the correlation coefficient
between OC and ucOC, and fasting insulin levels, homeostatic model assessment-insulin resistance (HOMA-IR),
HbA1c and fasting glucose levels (FPG) and (4) explore
potential sources of between-study heterogeneity. The
secondary objective is to compare the serum OC and
ucOC between PD and NGC, and between T2DM and PD.

Methods and analysis
We designed this systematic review and meta-analysis in
adherence to the guidelines of preferred reporting items
for systematic reviews and meta-analysis (PRISMA) and
meta-analysis of Observational Studies in Epidemiology
(MOOSE).31 32 The process of the proposed protocol is
shown in figure 1, and the PRISMA checklist shown in
online appendix 2.
Patients and public involvement statement
There is no patient or public involved in this systematic
review/meta-analysis.
Liu Y, et al. BMJ Open 2019;9:e023918. doi:10.1136/bmjopen-2018-023918

Eligibility criteria for studies included in the review
Inclusion and exclusion criteria
Participants
Participants should be adult humans (older than 18 years
old), with T2DM at the baseline or developed T2DM
afterwards; not have any conditions that can affect bone
metabolism or with medications that affect bone metabolism; and could be on anti-diabetic treatment.
Exclude:
1. Children or adolescents (younger than 18 years), and
pregnant or lactating women due to altered bone
turnover marker levels.
2. Patients with a disease that either affects bone metabolism or glucose metabolism.
3. Patients with type 1 diabetes and/or gestational diabetes as they are pathophysiologically different from
patients with type 2 diabetes (T2DM).
4. Patients with Cushing's disease or Cushing's syndrome as they have disordered metabolism.
5. Patients with hormonal disorders. For instance,
growth-hormone deficiency or excess.
6. Patients with hyperparathyroidism or hypoparathyroidism or other diseases that affect thyroid function
3
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Figure 1
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Study types
Observational studies are eligible for inclusion: cohort
studies (both prospective and retrospective cohort
studies), case-control studies and cross-sectional studies,
reporting eligible exposure(s) and outcome(s).
We will exclude reviews, commentaries, short surveys,
case reports, and letters.
Interventional
studies
(including
randomised
controlled trials) will be used if they provide eligible
cross-sectional data at the baseline before intervention.
4

Exposure(s)
OC levels are identified from ELISA, electrochemiluminescence immunoassay, immunoradiometric assay, radioimmunoassay and hydroxylapatite binding assay. The
standard unit for OC is ng/mL; thus, other presented
groups for OC (eg, nmol/L) will be converted to ng/mL.
Measures of OC
Total serum OC levels (ng/mL).
ucOC levels (ng/mL).
OC categorised as low (reference) and high groups.
Tertile, quartile or quantile are the common categories used for classifying different levels of TOC or
ucOC.

►►
►►
►►

Outcome(s)
Measures of T2DM
►► Diabetes status categorised as T2DM disease or normal
controls (reference).
►► As some studies may categorise diabetes states as
insulin-dependent diabetes mellitus and non-insulin
dependent diabetes mellitus (NIDDM), NIDDM will
be used and presented as T2DM.
Exclude type 1 diabetes and gestational diabetes as they
are pathophysiologically different compared with T2DM.
Secondary outcome(s)
Impaired glucose tolerance/impaired fasting glucose:
that is the pre-diabetic state with a higher risk of developing T2DM.
►► HbA1c levels categorised as T2DM, PD and healthy
controls (reference) by HbA1c rates over 6.5%,
between 5.7% and 6.5%, and below 5.7%, respectively.
►► Fasting plasma glucose levels categorised as diabetes,
PD and healthy controls (reference) by FPG levels
over 126 mg/dL, between 100 and 126 mg/dL, and
below 100 mg/dL, respectively.
►►

Study design
Search strategies
A comprehensive literature search within MEDLINE,
EMBASE and SCOPUS databases will be conducted to
source all possible relevant studies for the present review.
There is no language restriction, and non-English articles will be translated when possible and evaluated for
eligibility. There is no time restriction. We may include
conference proceedings and abstracts if necessary. We
will further conduct reference list searches of each available paper. If duplicate publications of the same study are
retrieved, the most relevant and up to date paper with
more complete data will be included. The detailed search
strategy is shown in table 1.
Process for selecting studies
One author will set-up the search strategy and store the
search results in Endnote X7. The search strategy and
recorded search results will then be checked by another
investigator. Two or more independent investigators will
perform the abstract screening (to remove duplicate
Liu Y, et al. BMJ Open 2019;9:e023918. doi:10.1136/bmjopen-2018-023918
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due to increased osteocalcin (OC) levels and changes
in metabolism.
7. Patients with liver dysfunction (alanine transaminase
level >3 times upper limit of normal).
8. Patients with impaired kidney function as described
below:
–– Chronic renal disease patients with glomerular
filtration rate below 30 mL/min·1.73 m2 at stage
four or five, or
–– Chronic renal disease patients with serum creatinine level over 2.07 mg/dL, or renal osteodystrophy, or kidney transplant as 21%–50%
of kidney transplant recipients may develop
secondary hyperparathyroidism after kidney
transplantation or when treated with dialysis or
hemodialysis.
9. Patients with Paget’s disease as they have disordered
bone metabolism.
10. Patients with osteomalacia as it is a severe bone disease and affects bone metabolism.
11. Patients with cancer or tumours. For example, bone
cancer metastases could affect bone turnover marker
levels.
12. Patients with HIV infection.
13. Patients with sepsis as they have disordered immune
response caused by infections.
14. Patients on medications that affect bone metabolism:
–– Antiresorptive or anabolic therapy for osteoporosis and selective oestrogen receptor modulators
(such as bisphosphonates, alendronate, etidronate, raloxifene, denosumab and teriparatide).
–– Oestrogen replacement therapy.
–– Glucocorticoids and thiazide diuretics.
15. Patients treated with surgery that directly affects hormone or thyroid function (ie, thyroidectomy, oophorectomy and hysterectomy).
Note:
1. We include intervention studies that reported baseline
data of OC and T2DM. Accordingly, we will eliminate
observational studies with more than 20% of the cohort taking above non-eligible therapy.
2. We included T2DM with diabetic medications, but
they will be assessed using subgroup analysis by
medication status. Anti-diabetic medications that
affect OC/ucOC levels include insulin therapy, glucagon-like peptide-1 (GLP-1) receptor agonists, and
thiazolidinediones.

Open access

MEDLINE (Ovid SP)
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.

exp osteocalcin
osteocalcin.mp
bone gla protein.mp
vitamin k?dependent bone protein*.mp
1 or 2 or 3 or 4
exp diabetes mellitus, Type 2/II
diabetes mellitus type 2/II.mp
(T2D* or NIDDM or ‘type 2’ or ‘type II’).tw
(non insulin$ depend$ or nonsinulin$depend$
or non insulin?depend$ or
noninsulin?depend$).tw
exp Hyperglycemia
hyperglycemia.mp
hypergly?emi*.tw
exp Hemoglobin A/or exp Hemoglobin A,
Glycosylated
HbA1c.mp
(‘HbA(1 c)’ or HbA1c or ‘HbA 1 c’ or
(glycosylated or glycated) adj h?emoglobin)).
tw
6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
or 15
5 and 16
limit 17 to humans

EMBASE (Ovid SP)
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.

exp osteocalcin
osteocalcin.mp
bone gla protein.mp
vitamin k?dependent bone
protein*.mp
1 and 2 and 3 and 4
exp non insulin dependent
diabetes mellitus
exp diabetes mellitus 2/II
(T2D* or NIDDM or ‘type 2’ or
‘type II’).tw
(prediabet* or pre diabet*).tw
hyperglyc?emi*.tw
6 or 7 or 8 or 9 or 10
5 and 11
limit 13 to (human and exclude
medline journals)

records of the same report and to include eligible articles), and full-text assessment (to acquire full-texts of
available studies and to construct citation lists of eligible
items). If a discrepancy arises, the disagreement will be
discussed with investigators by email or face-to-face meetings before reaching a final decision.
Data extraction
Two authors will independently extract data from studies
that are eligible for full-text assessment. If any discrepancy arises, a third reviewer will examine the data. All
extracted data will be saved in an Excel spreadsheet.
Eligible extracted items: author and publication year, study
design, study base, sample size, sex and postmenopausal
status in females, age, ethnicity, country, OC assay methods,
obesity measurements (body mass index or waist circumference), duration of diabetes, anti-diabetic medications status,
vitamin K supplementation/anti-vitamin K drugs, vitamin
D supplementation, TOC/ucOC levels in groups, any risk
estimate between TOC/ucOC and T2DM, any association
between TOC/ucOC and HbA1c and/or FPG in T2DM, any
association between TOC/ucOC and PD and/or impaired
glucose tolerance/impaired fasting glucose, any association between TOC/ucOC and standard glucose controls,
and any association between TOC/ucOC and HOMA-IR or
HOMA-beta in T2DM.
Risk of bias assessment
The methodological quality will be assessed using the Newcastle-Ottawa Scale (NOS). Cohort and case-control studies can
be assessed by three main parts in the NOS: selection, comparability and outcome/exposure.33 The maximum score is
Liu Y, et al. BMJ Open 2019;9:e023918. doi:10.1136/bmjopen-2018-023918

SCOPUS
(KEY ('osteocalcin')
OR KEY ('bone AND gla AND
protein')
OR KEY ('bone AND turnover AND
markers'))
AND (KEY ('diabetes AND mellitus')
OR KEY ('hemoglobin AND a1c')
OR KEY ('fasting AND plasma AND
glucose'))
AND KEY ('human') AND (LIMIT-TO
(DOCTYPE, ‘ar’))

nine points.33 A higher score indicates better methodological quality of the individual study.33 Cross-sectional studies
can be assessed using the modified NOS.34 The maximum
score is 10 points for the modified NOS, representing the
highest quality.34 The quality assessment template can be
found in the supplementary materials (online appendix 3).
Statistical analysis and data synthesis
Mean differences with 95% CI will be calculated between
T2DM and NGC, between PD and NGT, and between T2DM
and PD. Estimates of effect size will be expressed as relative
risk with 95% CI for cohort studies and OR with 95% CI for
case-control and cross-sectional studies. OR is expressed as
one increased SD of OC to the risk of developing T2DM.
Papers reporting other forms of OR will be translated to per
increased SD of OC if a logistic regression model is used.
Pearson’s correlation coefficient will be analysed by investigating the relationships between TOC or ucOC and fasting
insulin levels. Studies that only have medians and ranges
or IQRs will be transformed to means and SD.35 36 Furthermore, log-transformed data will be converted to raw statistics
before subjecting to analyses.37 We will assess publication bias
of mean differences and risk estimates by visual inspection
of the funnel plots38 39 Egger’s test will be used to assess the
publication bias when there is a large number of studies.38 We
will evaluate heterogeneity employing the I2 statistic by study
ID which quantifies inconsistency across studies to assess the
impact of heterogeneity on the meta-analysis.40 I2 represents
the degree of heterogeneity. I2 thresholds of 0%–40%,
30%–60%, 50%–90% and 75%–100% indicate possibilities
of low, moderate, substantial and considerable heterogeneity,
5
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Meta-regression/subgroup analysis
Meta-regression analysis and subgroup analysis will be
applied to assess the sources of heterogeneity. Meta-regression will be used for continuous factors such as age, sample
size and proportion of postmenopausal women. We will
use subgroup analyses to identify potential sources of clinical, methodological or statistical heterogeneity for categorical variables. We will also generate mix-effect models
to evaluate the influence of multiple factors on the effect
size. Random-effects models will be used, and p values of
<0.01 will be considered statistically significant for subgroup
analyses. Pre-planned subgroup analyses to explore statistical
heterogeneity will include stratification by:
►► Subgroups based on study design.
►► Subgroups based on age.
►► Subgroups based on sex. In addition, a subset based
on menopausal status will be assessed among females.
►► Subgroups based on ethnicity or race.
►► Subgroups based on diabetic status (normal, PD,
T2DM).
►► Subgroups based on anti-diabetic medication status in
T2DM.
►► Subgroups based on obesity measurements (body
mass index/waist circumference).
►► Subgroups based on OC assay methods.
►► Subgroups based on fasting measures and spot
measures.
►► Subgroups based on vitamin K supplementation/
anti-vitamin K drugs or vitamin D supplementation if
data are available.
Publication bias and confidence in cumulative evidence
Publication bias assessment is based on graphical test
(funnel plots) and Egger’s and Begg’s tests.38 39 The asymmetry of the funnel plot suggests a higher risk of publication bias and vice versa.38 Statistically, Egger’s and Begg’s
tests will be conducted using RStudio.
We will provide assurance of the quality of our results by
applying the Grading of Recommendations Assessment
Development and Evaluation (GRADE) tool. We will also
present an evidence profile summary using GRADEpro
software (http://ims.cochrane.org/gradepro). The
quality checklist includes the following items: risk of bias
assessment, consistency of results, directness of evidence
and precision of the results.

Discussion
The current systematic review/meta-analysis constitutes
an update and improvement to the current literature
in several ways. First, we will provide more evidence
compared with previous investigations in analysing the
6

potential role/s OC plays in T2DM by increasing the
number of eligible studies included in our up-to-date
analysis. Second, we will investigate the sources of heterogeneity, explicitly by an increase in the number of factors
such as age, sex, postmenopausal status in women, study
design, ethnicity or regions, OC assays and medications
on T2DM. This comprehensive analysis of heterogeneity
may uncover the factor(s) responsible for the differences
among already published studies. Third, we will produce
a report not only on TOC levels, but also on ucOC levels.
By including investigations on ucOC, we can determine
the endocrine roles of both OC and ucOC in humans,
if any. In addition, investigating the relationship in a
subgroup of patients with PD will provide more details
regarding the influence of OC (or ucOC) on glucose
levels in a progressive T2DM status. The major limitation of this review is that we will only be including observational studies as there is insufficient evidence from
clinical trials, which will restrict study results in specific
analyses. According to the search results for clinical
studies, if there are any eligible interventional studies, we
will include them but only use the baseline data in which
case we will regard those studies as cross-sectional studies.
Despite this disadvantage, there are still a large number
of studies that could be used to pool a quantitative analysis and provide evidence according to concerns with
heterogeneity. Our review will contribute to public health
and clinical research for further investigations regarding
the gap in the current literature.
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